Welcome to our dedicated page for Bridgebio Pharma news (Ticker: BBIO), a resource for investors and traders seeking the latest updates and insights on Bridgebio Pharma stock.
BridgeBio Pharma, Inc. (NASDAQ: BBIO) is a biopharmaceutical company focused on medicines for genetic diseases, and its news flow reflects both commercial activity and clinical development progress. Company updates frequently highlight Attruby (acoramidis), a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization.
Investors following BBIO news see regular disclosures on Attruby’s commercial performance and new clinical and real-world data from the ATTRibute-CM program and its open-label extension, including analyses of variant ATTR-CM populations and specific genetic subgroups. BridgeBio also reports on late-stage pipeline milestones, such as Phase 3 results for BBP-418 in LGMD2I/R9, topline data and regulatory plans for encaleret in autosomal dominant hypocalcemia type 1, and registrational studies of infigratinib in children with skeletal dysplasias.
News items often include participation in major medical and investor conferences, where BridgeBio presents moderated digital posters, scientific analyses, and corporate updates. Additional releases cover financial and corporate developments, including quarterly business updates, equity inducement grants, royalty monetization transactions related to acoramidis, and proposed offerings of convertible senior notes.
This BBIO news page on Stock Titan aggregates these announcements so readers can review clinical data disclosures, commercial updates, financing transactions, and governance developments in one place. For investors and observers tracking genetic disease drug development and ATTR-CM therapies, the news feed provides a concise view of BridgeBio’s reported progress and key events over time.
BridgeBio (Nasdaq: BBIO) on Nov 8, 2025 reported JAMA Cardiology and AHA data showing acoramidis (Attruby) significantly reduced mortality in variant ATTR-CM populations.
Key results: 59% lower all-cause mortality (ACM) in variant patients through Month 42 (p=0.032); in the p.V142I (V142I, V122I) subgroup a 69% reduction in ACM/first cardiovascular hospitalization through Month 30 (p=0.016) and 69% ACM reduction through Month 42 (p=0.045). Functional gains included +87 m 6-minute walk (p=0.0048) and +20 points KCCQ (p=0.0019) through Month 30. The V142I variant affects ~3–4% of U.S. Black individuals. Attruby is approved by FDA and major regulators in EU, UK, and Japan.
BridgeBio (Nasdaq: BBIO) said members of its management team will present at two investor conferences in November 2025: a fireside chat at the UBS Global Healthcare Conference in Palm Beach Gardens, FL on Monday, November 10 at 1:15 pm ET, and a fireside chat at the Jefferies Global Healthcare Conference in London on Tuesday, November 18 at 11:00 am ET.
The company said live webcasts will be available on its Investors > Events and Presentations page and replay recordings will remain on the BridgeBio website for 90 days after each event.
BridgeBio (Nasdaq: BBIO) will present ten moderated digital posters at the American Heart Association Scientific Sessions 2025 in New Orleans, Nov 7–10, 2025. The posters report clinical findings from the ATTRibute-CM study, including data on acoramidis showing reductions in all-cause mortality and cardiovascular hospitalizations, benefits across pre-specified subgroups, effects in the p.V142I (V122I) variant population, and NT-proBNP and quality-of-life improvements.
Presentations are scheduled Nov 8–10 with lead presenters from major centers (University College London, University of Pittsburgh, Cedars-Sinai, Columbia, Stanford, UChicago, U Washington, and others). A separate poster covers vutrisiran real-world healthcare resource use and mortality from a retrospective database analysis.
BridgeBio (Nasdaq: BBIO) reported Q3 2025 revenue of $120.7M, driven by $108.1M in U.S. Attruby net product sales. As of Oct 25, 2025, 5,259 prescriptions from 1,355 prescribers were written since FDA approval in Nov 2024. The company ended the quarter with $645.9M in cash, cash equivalents and marketable securities.
Clinical highlights include positive topline FORTIFY results for BBP-418 (glycosylated αDG increased 1.8x at 3 months; serum CK reduced 82%; ambulation and FVC improvements) and positive CALIBRATE results for encaleret (76% of participants achieved serum and urine calcium targets at Week 24 vs 4% on conventional therapy). BridgeBio plans NDAs for BBP-418 and encaleret in 1H 2026.
BridgeBio (Nasdaq: BBIO) reported positive topline Phase 3 results from CALIBRATE for encaleret in autosomal dominant hypocalcemia type 1 (ADH1) on October 29, 2025. The trial met its primary and key secondary endpoints with 76% of encaleret-treated participants reaching target serum and urine calcium at Week 24 versus 4% on conventional therapy (p<0.0001), and 91% achieving intact PTH above the lower reference limit versus 7% on conventional therapy (p<0.0001).
Additional readouts: mean corrected calcium increase of 0.82 mg/dL, mean 24-hour urine calcium reduction of 200 mg/day, 98% in target serum calcium at Week 20, and no discontinuations due to study drug. An NDA submission is planned in H1 2026; pediatric and chronic hypoparathyroidism registrational studies are planned in 2026.
BridgeBio (Nasdaq: BBIO) will release topline results from the ADH1 CALIBRATE Phase 3 trial before the market opens on Wednesday, October 28, 2025. Management will discuss the data on a conference call at 8:00 a.m. ET the same day.
Investors can access a live webcast via the company’s Investors > Events and Presentations page and a replay will be available on the BridgeBio website for 90 days after the event.
BridgeBio (Nasdaq: BBIO) reported positive topline Phase 3 FORTIFY results for oral small molecule BBP-418 in limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9) on Oct 27, 2025. Key clinical and biomarker readouts at the planned 12-month interim analysis met endpoints with a favorable safety profile.
Highlights include a 1.8x increase in glycosylated αDG (~17% of control, p<0.0001) sustained to 12 months, an 82% reduction in serum CK (p<0.0001), ambulatory improvement of +0.14 m/s from baseline and +0.27 m/s vs placebo (p<0.0001), and pulmonary benefit of ~+3% predicted FVC from baseline and ~+5% vs placebo (p=0.0071). The company intends to file an NDA with the FDA in H1 2026.
BridgeBio (Nasdaq: BBIO) announced two investor events next week: a webinar to share topline Phase 3 interim results from the LGMD2I/R9 FORTIFY study on Monday, October 27, 2025 at 8:00 AM ET, and its Q3 2025 earnings call on Wednesday, October 29, 2025 at 4:30 PM ET. Management will host both business update calls and provide webcasts accessible via the company’s Investors > Events and Presentations page.
A replay of each webcast will be available on the BridgeBio investor website for 90 days following the events.
BridgeBio Pharma (Nasdaq: BBIO) announced that on October 2, 2025 its compensation committee approved inducement RSU grants to 11 new employees totaling 23,884 shares of common stock under the Amended and Restated 2019 Inducement Equity Plan.
Vesting: 25% of each award vests on November 16, 2026, then 1/12 of the remaining shares vest quarterly thereafter, contingent on continued employment. All awards were granted as inducements pursuant to Nasdaq Listing Rule 5635(c)(4). The Plan was originally adopted November 2019 and amended on Feb 10, 2023 and Dec 13, 2023.
BridgeBio Pharma (Nasdaq: BBIO) presented groundbreaking data from the ATTRibute-CM study showing that acoramidis, their oral TTR stabilizer, demonstrates rapid efficacy in treating ATTR-CM (transthyretin amyloid cardiomyopathy). The drug showed significant cardiovascular benefits within the first month of treatment.
Key findings include a 49% hazard reduction in cardiovascular mortality or recurrent hospitalizations through Month 30 (p<0.0001), with 53 events avoided per 100 treated participants. At Month 42, continuous acoramidis treatment reduced cardiovascular mortality by 45% compared to placebo-to-acoramidis switch (p=0.0011).
Acoramidis, marketed as Attruby® in the US and BEYONTTRA® in Europe, Japan, and the UK, has received regulatory approval with labels specifying near-complete TTR stabilization.
FAQ
What is the current stock price of Bridgebio Pharma (BBIO)?
What is the market cap of Bridgebio Pharma (BBIO)?
